An 82-year-old man with age-related macular degeneration presented with painful vision
loss in the right eye 42 days after his third brolucizumab injection (Beovu, Novartis,
Basel, Switzerland). Visual acuity was light perception (baseline, 20/150). Examination
revealed moderate to severe vitritis, arterial sheathing, diffuse arterial and venous
narrowing, and perivenular hemorrhages (Fig. 1A,1B). Fluorescein angiography demonstrated extensive arterial and venous filling defects
with peripheral nonperfusion (Fig. 1C, 1D). Occlusive retinal vasculitis associated with brolucizumab injection can lead to
irreversible vision loss. Before injecting, a meticulous examination for signs of
inflammation is crucial, and patients must be informed about this potential complication.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of OphthalmologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
Published online: May 07, 2021
Accepted:
April 7,
2021
Received:
March 26,
2021
Identification
Copyright
© 2021 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.
